N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide

ID: ALA272980

Cas Number: 9003-99-0

PubChem CID: 9865515

Product Number: np006164, Order Now?

Max Phase: Phase

Molecular Formula: C23H20N6O

Molecular Weight: 396.45

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Mocetinostat | MGCD-0103 | MGCD0103 | Mocetinostat|726169-73-9|MGCD0103|MGCD-0103|MGCD 0103|Peroxidase|N-(2-AMINOPHENYL)-4-([[4-(PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO]METHYL)BENZAMIDE|9003-99-0|Mocetinostat (MGCD0103)|N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide|MG0103|MGCD0103 (Mocetinostat)|Mocetinostat (MGCD-0103)|MG 0103|A6GWB8T96J|CHEMBL272980|MG-0103|N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide|726169-73-9 (free base)|N-(2-aminophenyl)-Show More⌵

Synonyms from Alternative Forms(2): Mocetinostat dihbr | Mocetinostat dihydrobromide

Canonical SMILES:  Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1

Standard InChI:  InChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)

Standard InChI Key:  HRNLUBSXIHFDHP-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
    2.5000   -0.4125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5042    0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7833   -0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2167    0.4125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2125   -0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9333    0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7833   -1.6500    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7875    0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9292   -0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0708   -0.4125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5042    1.6500    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6458    0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3583   -0.4125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0750    0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7875   -0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2125   -1.6500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5000   -2.0625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6458   -0.4125    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3542   -0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3583   -0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3583    0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0750   -0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6417   -0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9333    1.6500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9292    0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3583    0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3625    0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6417    0.8250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6458    2.0625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.3625    1.6500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  8  1  0
  3  1  1  0
  4  2  1  0
  5  1  2  0
  6  4  1  0
  7  3  2  0
  8 14  1  0
  9  5  1  0
 10  3  1  0
 11  2  2  0
 12  6  2  0
 13 23  2  0
 14 21  2  0
 15 22  1  0
 16  5  1  0
 17  7  1  0
 18 12  1  0
 19 10  1  0
 20 19  1  0
 21 20  1  0
 22 20  2  0
 23  9  1  0
 24  6  1  0
 25  9  2  0
 26 28  2  0
 27 12  1  0
 28 25  1  0
 29 24  2  0
 30 29  1  0
 16 17  2  0
 26 13  1  0
 15  8  2  0
 27 30  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA272980

   MOCETINOSTAT

2. Alternative Forms:

   

   ALA272980

   MOCETINOSTAT DIHYDROBROMIDE

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: Yes

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 396.45

Molecular Weight (Monoisotopic): 396.1699

AlogP: 3.99

#Rotatable Bonds: 6

Polar Surface Area: 105.82

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 4.37

CX LogP: 3.00

CX LogD: 3.00

Aromatic Rings: 4

Heavy Atoms: 30

QED Weighted: 0.43

Np Likeness Score: -1.45

References

1. Paris M, Porcelloni M, Binaschi M, Fattori D..  (2008)  Histone deacetylase inhibitors: from bench to clinic.,  51  (6): [PMID:18247554] [10.1021/jm7011408]

2. Jones P, Altamura S, De Francesco R, Gallinari P, Lahm A, Neddermann P, Rowley M, Serafini S, Steinkühler C..  (2008)  Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.,  18  (6): [PMID:18308563] [10.1016/j.bmcl.2008.02.025]

3. Zhou N, Moradei O, Raeppel S, Leit S, Frechette S, Gaudette F, Paquin I, Bernstein N, Bouchain G, Vaisburg A, Jin Z, Gillespie J, Wang J, Fournel M, Yan PT, Trachy-Bourget MC, Kalita A, Lu A, Rahil J, MacLeod AR, Li Z, Besterman JM, Delorme D..  (2008)  Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.,  51  (14): [PMID:18570366] [10.1021/jm800251w]

4. Raeppel S, Zhou N, Gaudette F, Leit S, Paquin I, Larouche G, Moradei O, Fréchette S, Isakovic L, Delorme D, Fournel M, Kalita A, Lu A, Trachy-Bourget MC, Yan PT, Liu J, Rahil J, Wang J, Besterman JM, Murakami K, Li Z, Vaisburg A..  (2009)  SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).,  19  (3): [PMID:19114304] [10.1016/j.bmcl.2008.12.048]

5. Wahhab A, Smil D, Ajamian A, Allan M, Chantigny Y, Therrien E, Nguyen N, Manku S, Leit S, Rahil J, Petschner AJ, Lu AH, Nicolescu A, Lefebvre S, Montcalm S, Fournel M, Yan TP, Li Z, Besterman JM, Déziel R..  (2009)  Sulfamides as novel histone deacetylase inhibitors.,  19  (2): [PMID:19084395] [10.1016/j.bmcl.2008.11.081]

6. Tessier P, Smil DV, Wahhab A, Leit S, Rahil J, Li Z, Déziel R, Besterman JM..  (2009)  Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.,  19  (19): [PMID:19699639] [10.1016/j.bmcl.2009.08.010]

7. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R..  (2010)  Chemical phylogenetics of histone deacetylases.,  6  (3): [PMID:20139990] [10.1038/nchembio.313]

8. Shultz M, Fan J, Chen C, Cho YS, Davis N, Bickford S, Buteau K, Cao X, Holmqvist M, Hsu M, Jiang L, Liu G, Lu Q, Patel C, Suresh JR, Selvaraj M, Urban L, Wang P, Yan-Neale Y, Whitehead L, Zhang H, Zhou L, Atadja P..  (2011)  The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.,  21  (16): [PMID:21742496] [10.1016/j.bmcl.2011.06.015]

9. Shultz MD, Cao X, Chen CH, Cho YS, Davis NR, Eckman J, Fan J, Fekete A, Firestone B, Flynn J, Green J, Growney JD, Holmqvist M, Hsu M, Jansson D, Jiang L, Kwon P, Liu G, Lombardo F, Lu Q, Majumdar D, Meta C, Perez L, Pu M, Ramsey T, Remiszewski S, Skolnik S, Traebert M, Urban L, Uttamsingh V, Wang P, Whitebread S, Whitehead L, Yan-Neale Y, Yao YM, Zhou L, Atadja P..  (2011)  Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.,  54  (13): [PMID:21650221] [10.1021/jm200388e]

10. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 

11. PubChem BioAssay data set, 

12. Bergman JA, Woan K, Perez-Villarroel P, Villagra A, Sotomayor EM, Kozikowski AP..  (2012)  Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.,  55  (22): [PMID:23009203] [10.1021/jm301098e]

13. Li Y, Zhou Y, Qian P, Wang Y, Jiang F, Yao Z, Hu W, Zhao Y, Li S..  (2013)  Design, synthesis and bioevalution of novel benzamides derivatives as HDAC inhibitors.,  23  (1): [PMID:23206867] [10.1016/j.bmcl.2012.10.114]

14. Marson CM, Matthews CJ, Yiannaki E, Atkinson SJ, Soden PE, Shukla L, Lamadema N, Thomas NS..  (2013)  Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.,  56  (15): [PMID:23829483] [10.1021/jm400634n]

15. Zhang X, Bao B, Yu X, Tong L, Luo Y, Huang Q, Su M, Sheng L, Li J, Zhu H, Yang B, Zhang X, Chen Y, Lu W..  (2013)  The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.,  21  (22): [PMID:24095018] [10.1016/j.bmc.2013.09.023]

16. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

17. Zhang X, Kong Y, Zhang J, Su M, Zhou Y, Zang Y, Li J, Chen Y, Fang Y, Zhang X, Lu W..  (2015)  Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.,  95  [PMID:25805446] [10.1016/j.ejmech.2015.03.035]

18. Marson CM, Matthews CJ, Atkinson SJ, Lamadema N, Thomas NS..  (2015)  Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.,  58  (17): [PMID:26287310] [10.1021/acs.jmedchem.5b00545]

19. Zhang X, Lv P, Li D, Zhang W, Zhu H.  (2015)  Navigating into the chemical space between MGCD0103 and SAHA: novel histone deacetylase inhibitors as a promising lead,  6  (10): [10.1039/C5MD00247H]

20. Unpublished dataset, 

21.  (2016)  Selective histone deactylase 6 inhibitors, 

22. Lu W, Yao X, Ouyang P, Dong N, Wu D, Jiang X, Wu Z, Zhang C, Xu Z, Tang Y, Zou S, Liu M, Li J, Zeng M, Lin P, Cheng F, Huang J..  (2017)  Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.,  60  (5): [PMID:28218840] [10.1021/acs.jmedchem.6b01507]

23. Tian Y, Lv W, Li X, Wang C, Wang D, Wang PG, Jin J, Shen J..  (2017)  Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.,  27  (13): [PMID:28501514] [10.1016/j.bmcl.2017.05.004]

24. Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek.  (2020)  Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection,  [10.21203/rs.3.rs-23951/v1]

25. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

26. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

27. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

28. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

29. Ellen Van Damme.  (2021)  Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity,  [10.6019/CHEMBL4651402]

30. Ho TCS,Chan AHY,Ganesan A.  (2020)  Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.,  63  (21.0): [PMID:32608981] [10.1021/acs.jmedchem.0c00830]

31. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius.  (2021)  HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators,  [10.6019/CHEMBL4808148]

32. Yan W, Ling L, Wu Y, Yang K, Liu R, Zhang J, Zhao S, Zhong G, Zhao S, Jiang H, Xie C, Cheng J..  (2021)  Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A_2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents.,  64  (22.0): [PMID:34783558] [10.1021/acs.jmedchem.1c01155]

33. Hicks EG, Kandel SE, Lampe JN..  (2022)  Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M^pro) inhibitors.,  66  [PMID:35427739] [10.1016/j.bmcl.2022.128732]

34. Zhang J, Luo Z, Duan W, Yang K, Ling L, Yan W, Liu R, Wüthrich K, Jiang H, Xie C, Cheng J..  (2022)  Dual-acting antitumor agents targeting the A_2A adenosine receptor and histone deacetylases: Design and synthesis of 4-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine derivatives.,  236  [PMID:35390714] [10.1016/j.ejmech.2022.114326]

Source

Source(9):

• Scientific Literature
• PubChem BioAssays
• Clinical Candidates
• USP Dictionary of USAN and International Drug Names
• AstraZeneca Deposited Data
• BindingDB Database
• SARS-CoV-2 Screening Data 2020-21
• IMI-CARE SARS-CoV-2 Data
• Fraunhofer HDAC6